- Press Releases
(SeeNews) - Jan 25, 2013 - British wind power developer Infinergy said Thursday it was holding talks to sell electricity from its planned 11.5-MW wind farm in western England to GlaxoSmithKline (LON:GSK).
The British pharma major has expressed interest in buying power from the wind facility as its was searching for alternative ways of supplying electricity to its production site in Ulverston, north-western England, where it manufactures active pharmaceutical ingredients for antibiotics.
Infinergy's proposed Furness wind farm is a joint project with local cooperative Baywind. Infinergy has applied for the installation of three new machines and its partner will seek to replace five 2.5-MW turbines at its Harlock Hill wind park with new machines with higher capacity.
If the project is approved, GlaxoSmithKline could purchase the whole output of Infinergy's three wind turbines, equal to 6.9 MW, thus cutting its carbon dioxide emissions by 25%.
The pharmaceutical company has set a goal of lowering the carbon footprint of its Ulverston plant by 30% by end-2014, according to a company spokesman.